Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thyroxine replacement therapy in infants with euthyroid sick syndrome after congenital heart surgery
ChiCTR2000034223Phase 4Not yet recruiting
- Sponsor
- Cardio-Thoracic Surgery, Children's Hospital of Nanjing Medical University
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in Cardiovascular Malformation (CVM) and euthyroid sick syndrome (NTIS) comparing Placebo control group with Thyroxine treatment group (2 arms). Primary endpoint: Thyroid function (TT3, FT3, TT4, FT4, TSH). Planned start Jun 2020; status: not yet recruiting.
02
Drugs
levothyroxine sodium
03
Conditions
Cardiovascular Malformation (CVM)euthyroid sick syndrome (NTIS)
Beyond the preview
Go deeper on ChiCTR2000034223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034223.